Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.

IF 0.3 4区医学 Q4 Medicine

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-09-16 DOI:10.1159/000355156

Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, Suleyman Buyukberber

{"title":"Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.","authors":"Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, Suleyman Buyukberber","doi":"10.1159/000355156","DOIUrl":null,"url":null,"abstract":"Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC).Patients and methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis.Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS.Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"554-8"},"PeriodicalIF":0.3000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355156","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000355156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/9/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC).

Patients and methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis.

Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS.

Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.

查看原文本刊更多论文

辅助曲妥珠单抗治疗her2阳性早期乳腺癌患者无复发生存的预后因素

背景:本研究的目的是确定影响her2阳性早期乳腺癌(EBC)患者接受52周曲妥珠单抗治疗的无复发生存期(RFS)的预后因素。患者和方法:对10个中心所有EBC患者的病历进行分析。对424例接受52周辅助曲妥珠单抗治疗her2阳性EBC的女性患者的病理和临床肿瘤特征进行了评估。生存率采用Kaplan-Meier法估计。采用log-rank检验对RFS进行单因素分析。采用Cox回归分析评估影响RFS的独立预后和预测因素。结果:中位随访时间为33.1个月(范围9.2 ~ 75.9个月)。3年RFS和总生存率分别为87%和97%。在多因素分析中，70岁及以上患者(p = 0.017，相对危险度(RR) 2.7, 95%可信区间(CI) 1.19-6.13)、> 9个淋巴结阳性患者(p = 0.001, RR 2.52, 95% CI 1.42-4.46)和孕激素受体阴性肿瘤患者(p = 0.006, RR 2.33, 95% CI 1.27-4.27)的RFS较差。结论:尽管接受了52周的曲妥珠单抗辅助治疗，her2阳性EBC患者侵袭性EBC的典型预后不良因素仍然存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊